- Grimes M, Hall B, Foltz L, Levy T, Rikova K, Gaiser J, Cook W, Wheeler T., Clark N R, Lachmann A, Zhang B, Hornbeck P, Ma'ayan A, Comb M. Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks. 2018; Sci Signal, 11(531). https://doi.org/10.1126/scisignal.aaq1087
- Haque I, Ghosh A, Acup S, Banerjee S, Dhar K, Ray A, Sarkar S, Kambhampati S, Banerjee S K. Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. BMC Cancer, 2018; 18(1), 99. https://doi.org/10.1186/s12885-018-3993-6
- Levi M, Shalgi R, Brenner B, Perl G, Purim O, Amit L, Stemmer S M, Ben-Aharon I. The impact of oxaliplatin on the gonads: from bedside to the bench. Mol Hum Reprod, 2015; 21(12), 885-893. https://doi.org/10.1093/molehr/gav055
- Feng L X, Li M, Liu Y J, Yang S M, Zhang N. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int J Mol Sci, 2014; 15(3), 4201-4220. https://doi.org/10.3390/ijms15034201
- Sung H, Ferlay J, Siegel R L, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021; 71(3), 209-249. https://doi.org/10.3322/caac.21660
- Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol, 2019; 14(2), 89-103. https://doi.org/10.5114/pg.2018.81072
- Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites E C. Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021; 12(1), 5961. https://doi.org/10.1038/s41467-021-26213-y
- Beijers A J, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer, 2015; 22(7), 1999-2007. https://doi.org/10.1007/s00520-014-2242-z
- Danciu C, Muntean D, Alexa E, Farcas C, Oprean C, Zupko I, Bor A, Minda D, Proks M, Buda V, Hancianu M, Cioanca O, Soica C, Popescu S, Dehelean C A. Phytochemical Characterization and Evaluation of the Antimicrobial, Antiproliferative and Pro-Apoptotic Potential of Ephedra alata Decne. Hydroalcoholic Extract against the MCF-7 Breast Cancer Cell Line. Molecules, 2018; 24(1). https://doi.org/10.3390/molecules24010013
- Azman A S, Othman I, Fang C M, Chan K G, Goh B H, Lee L H. Antibacterial, Anticancer and Neuroprotective Activities of Rare Actinobacteria from Mangrove Forest Soils. Indian J Microbiol,2017; 57(2), 177-187. https://doi.org/10.1007/s12088-016-0627-z
- Fujie Y, Yamamoto H, Ngan C Y, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol, 2005; 35(8), 453-463. https://doi.org/10.1093/jjco/hyi130
- Hopkins B D, Goncalves M D, Cantley L C. Obesity and Cancer Mechanisms: Cancer Metabolism. J Clin Oncol, 2016; 34(35), 4277-4283. https://doi.org/10.1200/jco.2016.67.9712
- Kratz F, Müller I A, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem, 2008; 3(1), 20-53. https://doi.org/10.1002/cmdc.200700159
- MacKenzie S H, Clark A C. Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets, 2008; 8(2), 98-109. https://doi.org/10.2174/156800908783769391
- Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4): 495-516
- Ahmed AA, Wang X, Lu Z, et al. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res. 2011; 71(17): 5806–5817.
- Oechsle K, Kollmannsberger C, Honecker F, Mayer F. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol, 2011; 60(4):850-5. doi: 10.1016/j.eururo.2011.06.019.
- Zhang Y, Li C, Qin Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer. J. E. V., (2021); 10 (5). https://doi.org/10.1002/jev2.12073
- Shi M, Yang Z, Lu S. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC Cancer, 2021; 21, 1344. https://doi.org/10.1186/s12885-021-09027-5
- Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Colorectal Cancer. 2008;7(1): 44-7. doi: 10.3816/CCC.2008.n.006.
- Cook L M, Hurst D R, Welch D R. Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol, 2011; 21(2), 113-122. https://doi.org/10.1016/j.semcancer.2010.12.005
- Arnold J, David P. The P53 family: a subject collection from cold spring Harbor perspectives in biology laboratory press. Molecular cancer, 2010; 126:273-84.
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) J. Pharmacol. Exp. Ther. 2006; 19: 879–886. doi:10.1124/jpet.106.110346.
|
